Pfizer False Claims Act Ruling Keeps High Evidentiary Standards, Limits Employee Protections
Executive Summary
Appeals court rules that aggregate data of government expenditures are not a substitute evidence of actual false claims and that FCA does protect whistleblowers who just report regulatory violations.
You may also be interested in...
Pfizer Settlement Means New Oversight; Does It Mean A New Marketing Plan?
The government may be hoping the third time's the charm as it enters into a new corporate integrity agreement with Pfizer
Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.
Xpovio Clinical Development Timeline
Chronicle of the development and review of Karyopharm's Xpovio (selinexor) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies.